Effect of Low Molecular Weight Heparin Calcium Combined with Argatroban on the Treatment, Vascular Endothelial Function, Inflammatory Factors and Serum Neurological Function in Patients with Acute Cerebral Infarction
Effect of Low Molecular Weight Heparin Calcium Combined with Argatroban on the Treatment, Vascular Endothelial Function, Inflammatory Factors and Serum Neurological Function in Patients with Acute Cerebral Infarction
Xiaoli Yao1, Xiaofang Yue2, Yue Yang3 and Guobin Zhang3,*
ABSTRACT
The objective of this study was to observe the effects of low-molecular-weight heparin calcium (LMWHC) combined with argatroban on the treatment, vascular endothelial function, inflammatory factors and neurological function in patient with acute cerebral infarction. A total of 80 patients with acute cerebral infarction were randomly divided into 2 groups each of 40 cases, regardless of gender, aged from 55-75 years, who underwent treatment in hospital from January 2018 to December 2020. Each group received routine treatment, in which the treatment group received LMWHC alongwith argatroban. The score of neurological deficit (NIHSS) and serum neurological function, endothelial injury and inflammatory marker levels, and the clinical efficacy after treatment of 14 days were compared between groups. After treatment of 14 days, the vascular endothelial function (NO, ET-1, FMD) and inflammatory factors (hs-CRP, TNF-α, IL-6, MMP-9, Lp-PLA2) in the patients of the treatment group were significantly higher than the control group. NIHSS and serum neurological function (copeptin, NT-proBNP, PAO, S-100B) in the patients of the treatment group were significantly higher than that of the control group (P<0.05). Adverse reaction of LMWHC and argatroban was not found in the course of treatment. We conclude that LMWHC combined with argatroban are safe and effective in the treatment of acute cerebral infarction.
To share on other social networks, click on any share button. What are these?
